{"id":1970,"date":"2024-06-05T20:06:16","date_gmt":"2024-06-05T20:06:16","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=1970"},"modified":"2026-02-22T23:08:26","modified_gmt":"2026-02-22T23:08:26","slug":"validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/","title":{"rendered":"Validation of the BOADICEA model in a prospective cohort of BRCA1\/2 pathogenic variant carriers (Contributed by Dr Xin Yang)"},"content":{"rendered":"

BOADICEA is a multifactorial breast cancer risk model for predicting the future breast cancer risk based on the joint effects of cancer family history, lifestyle, hormonal and reproductive risk factors, polygenic risk score and rare pathogenic variants. Here, Yang et al validated\u00a0 for the first time the full multifactorial model in 1,614 BRCA1 <\/em>and 1,365 BRCA2<\/em> PV carriers, demonstrating that BOADICEA is well calibrated, predicts risks accurately in different risk categories and discriminates well between affected and unaffected BRCA1\/2<\/em> carriers. Implemented in www.canrisk.org BOADICEA allows for more personalised breast cancer risk assessment for BRCA1\/2<\/em> carriers. (https:\/\/jmg.bmj.com\/content\/early\/2024\/06\/03\/jmg-2024-109943<\/a> )<\/p>\n

\"\"<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

BOADICEA is a multifactorial breast cancer risk model for predicting the future breast cancer risk based on the joint effects of cancer family history, lifestyle, hormonal and reproductive risk factors, polygenic risk score and rare pathogenic variants. Here, Yang et al validated\u00a0 for the first time the full multifactorial model in 1,614 BRCA1 and 1,365 […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1970","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"\nValidation of the BOADICEA model in a prospective cohort of BRCA1\/2 pathogenic variant carriers (Contributed by Dr Xin Yang) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Validation of the BOADICEA model in a prospective cohort of BRCA1\/2 pathogenic variant carriers (Contributed by Dr Xin Yang) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"BOADICEA is a multifactorial breast cancer risk model for predicting the future breast cancer risk based on the joint effects of cancer family history, lifestyle, hormonal and reproductive risk factors, polygenic risk score and rare pathogenic variants. Here, Yang et al validated\u00a0 for the first time the full multifactorial model in 1,614 BRCA1 and 1,365 [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-05T20:06:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-22T23:08:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/jmg\/files\/2024\/06\/Untitled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2136\" \/>\n\t<meta property=\"og:image:height\" content=\"902\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2024\\\/06\\\/05\\\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2024\\\/06\\\/05\\\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Validation of the BOADICEA model in a prospective cohort of BRCA1\\\/2 pathogenic variant carriers (Contributed by Dr Xin Yang)\",\"datePublished\":\"2024-06-05T20:06:16+00:00\",\"dateModified\":\"2026-02-22T23:08:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2024\\\/06\\\/05\\\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\\\/\"},\"wordCount\":122,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2024\\\/06\\\/05\\\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2024\\\/06\\\/Untitled-300x127.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2024\\\/06\\\/05\\\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2024\\\/06\\\/05\\\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2024\\\/06\\\/05\\\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\\\/\",\"name\":\"Validation of the BOADICEA model in a prospective cohort of BRCA1\\\/2 pathogenic variant carriers (Contributed by Dr Xin Yang) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2024\\\/06\\\/05\\\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2024\\\/06\\\/05\\\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2024\\\/06\\\/Untitled-300x127.jpg\",\"datePublished\":\"2024-06-05T20:06:16+00:00\",\"dateModified\":\"2026-02-22T23:08:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2024\\\/06\\\/05\\\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2024\\\/06\\\/05\\\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2024\\\/06\\\/05\\\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2024\\\/06\\\/Untitled.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2024\\\/06\\\/Untitled.jpg\",\"width\":2136,\"height\":902},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2024\\\/06\\\/05\\\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Validation of the BOADICEA model in a prospective cohort of BRCA1\\\/2 pathogenic variant carriers (Contributed by Dr Xin Yang)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Validation of the BOADICEA model in a prospective cohort of BRCA1\/2 pathogenic variant carriers (Contributed by Dr Xin Yang) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/","og_locale":"en_US","og_type":"article","og_title":"Validation of the BOADICEA model in a prospective cohort of BRCA1\/2 pathogenic variant carriers (Contributed by Dr Xin Yang) - JMG Contact blog","og_description":"BOADICEA is a multifactorial breast cancer risk model for predicting the future breast cancer risk based on the joint effects of cancer family history, lifestyle, hormonal and reproductive risk factors, polygenic risk score and rare pathogenic variants. Here, Yang et al validated\u00a0 for the first time the full multifactorial model in 1,614 BRCA1 and 1,365 [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/","og_site_name":"JMG Contact blog","article_published_time":"2024-06-05T20:06:16+00:00","article_modified_time":"2026-02-22T23:08:26+00:00","og_image":[{"width":2136,"height":902,"url":"https:\/\/blogs.bmj.com\/jmg\/files\/2024\/06\/Untitled.jpg","type":"image\/jpeg"}],"author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Validation of the BOADICEA model in a prospective cohort of BRCA1\/2 pathogenic variant carriers (Contributed by Dr Xin Yang)","datePublished":"2024-06-05T20:06:16+00:00","dateModified":"2026-02-22T23:08:26+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/"},"wordCount":122,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2024\/06\/Untitled-300x127.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/","url":"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/","name":"Validation of the BOADICEA model in a prospective cohort of BRCA1\/2 pathogenic variant carriers (Contributed by Dr Xin Yang) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2024\/06\/Untitled-300x127.jpg","datePublished":"2024-06-05T20:06:16+00:00","dateModified":"2026-02-22T23:08:26+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/#primaryimage","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2024\/06\/Untitled.jpg","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2024\/06\/Untitled.jpg","width":2136,"height":902},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2024\/06\/05\/validation-of-the-boadicea-model-in-a-prospective-cohort-of-brca1-2-pathogenic-variant-carriers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Validation of the BOADICEA model in a prospective cohort of BRCA1\/2 pathogenic variant carriers (Contributed by Dr Xin Yang)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1970","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=1970"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1970\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=1970"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=1970"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=1970"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}